<p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - 获取免费报告) 首席财务官 Sandip Kapadia 于 1 月 26 日星期一出售了 3,746 股 Harmony Biosciences 股票。股票以平均价格 $37.15 出售，总价值为 $139,163.90。出售完成后，首席财务官直接持有该公司 24,521 股股票，价值 $910,955.15。此次交易使其持股减少了 13.25%。该出售在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
<p>Sandip Kapadia 最近还进行了以下交易：</p>
<ul>
<li>在 1 月 15 日星期四，Sandip Kapadia 出售了 20,961 股 Harmony Biosciences 股票。股票以平均价格 $35.92 出售，总价值为 $752,919.12。</li>
</ul>
<p>获取 <strong>Harmony Biosciences</strong> 警报：</p>
<h2>Harmony Biosciences 股价下跌 2.2%</h2>
<p>在周三的交易中，NASDAQ HRMY 股价下跌 $0.84，跌至 $36.84。该股票的交易量为 503,087 股，而其平均交易量为 597,958 股。该公司的速动比率为 3.72，流动比率为 3.75，债务与股本比率为 0.18。该公司的市值为 21.2 亿美元，市盈率为 11.58，市盈增长比率为 0.35，贝塔系数为 0.84。该公司 50 日移动平均价格为 $37.30，200 日移动平均价格为 $34.23。Harmony Biosciences Holdings, Inc. 的 12 个月低点为 $25.52，12 个月高点为 $40.87。</p>
<p>Harmony Biosciences (NASDAQ:HRMY - 获取免费报告) 最近一次发布季度财报是在 11 月 4 日星期二。该公司报告本季度每股收益为 $0.87，低于市场共识预期的 $0.92，差距为 ($0.05)。Harmony Biosciences 的净利润率为 22.50%，股本回报率为 24.88%。该公司在本季度的收入为 $239.46 百万美元，而分析师预期为 $222.68 百万美元。整体来看，股票研究分析师预测 Harmony Biosciences Holdings, Inc. 本年度每股收益将达到 2.43。</p>
<h2>对 Harmony Biosciences 的对冲基金看法</h2>
<p>一些机构投资者和对冲基金最近增加或减少了在 HRMY 的持股。Amundi 在第一季度将其在 Harmony Biosciences 的持股提高了 115.6%。Amundi 现在拥有 39,668 股该公司的股票，价值 $1,229,000，此前在上个季度购买了额外的 21,266 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Harmony Biosciences 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 现在拥有 22,651 股该公司的股票，价值 $752,000，此前在上个季度购买了额外的 984 股。Empowered Funds LLC 在第一季度收购了 Harmony Biosciences 的新股份，价值 $2,330,000。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度将其在 Harmony Biosciences 的持股提高了 53.0%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 现在拥有 95,389 股该公司的股票，价值 $3,166,000，此前在上个季度收购了额外的 33,058 股。最后，阿拉斯加州财政部在第二季度将其在 Harmony Biosciences 的持股提高了 8.1%。阿拉斯加州财政部现在拥有 22,897 股该公司的股票，价值 $722,000，此前在上个季度收购了额外的 1,724 股。86.23% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>一些研究分析师最近对 HRMY 股票发布了报告。瑞穗证券在 12 月 1 日星期一将 Harmony Biosciences 的目标价从 $39.00 提高至 $46.00，并在报告中给予该公司 &#34;跑赢大盘&#34; 的评级。HC Wainwright 在 12 月 3 日星期三的研究报告中重申了对 Harmony Biosciences 股票的 &#34;买入&#34; 评级。Truist Financial 在 1 月 8 日星期四的研究报告中将 Harmony Biosciences 的目标价从 $48.00 降至 $45.00，并为该公司设定了 &#34;买入&#34; 评级。瑞银集团在 10 月 15 日星期三的报告中将 Harmony Biosciences 股票的目标价从 $50.00 降至 $43.00，并对该股票设定了 &#34;买入&#34; 评级。最后，华尔街 Zen 在 12 月 13 日星期六的研究报告中将 Harmony Biosciences 股票的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。两位研究分析师对该股票给予了强烈买入评级，七位给予了买入评级，两位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;买入&#34;，平均目标价为 $45.25。</p>
<p><strong>查看我们最新的 Harmony Biosciences 股票报告</strong></p>
<h2>Harmony Biosciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>Harmony Biosciences Holdings, Inc 是一家商业阶段的生物制药公司，专注于开发和提供针对罕见神经和内分泌疾病患者的治疗方案。公司成立于 2017 年，总部位于宾夕法尼亚州普利茅斯会议，Harmony Biosciences 于 2020 年上市，并在纳斯达克以 HRMY 的股票代码交易。公司的使命是识别和推进能够满足现有治疗方案无法满足的患者群体的关键未满足需求的药物。</p>
<p>该公司的旗舰产品是 WAKIX（pitolisant），这是美国批准的首个也是唯一的组胺 H3 受体拮抗剂/反向激动剂。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 Harmony Biosciences 更好</li>
<li>您的签名缺失 - 请在为时已晚之前采取行动</li>
<li>在星期一上午 9:30 购买此股票！</li>
<li>特朗普刚刚签署了它</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>请勿删除，立即阅读</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 $1,000 在 Harmony Biosciences 吗？</h2>
<p>在你考虑 Harmony Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Harmony Biosciences 并不在名单上。</p>
<p>虽然 Harmony Biosciences 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HRMY

<p>Harmony Biosciences 的首席财务官 Sandip Kapadia 出售了 3,746 股，价格为每股 37.15 美元，总计 139,163.90 美元，减少了 13.25% 的持股，剩余 24,521 股，价值 910,955.15 美元。此交易已向美国证券交易委员会（SEC）披露。最近，他还以平均价格 35.92 美元出售了 20,961 股。该股票目前交易价格为 36.84 美元，下跌 2.2%。Harmony 报告的季度每股收益（EPS）为 0.87 美元，未达到预期，收入为 2.3946 亿美元。分析师们设定了新的目标价格，其中瑞穗证券将其目标价上调至 46.00 美元，并维持 “跑赢大盘” 的评级</p>

<p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction on Monday, January 26th. The shares were sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the sale, the chief financial officer directly owned 24,521 shares of the company's stock, valued at $910,955.15. The trade was a 13.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - 获取免费报告) 首席财务官 Sandip Kapadia 于 1 月 26 日星期一出售了 3,746 股 Harmony Biosciences 股票。股票以平均价格 $37.15 出售，总价值为 $139,163.90。出售完成后，首席财务官直接持有该公司 24,521 股股票，价值 $910,955.15。此次交易使其持股减少了 13.25%。该出售在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
</div><p>Sandip Kapadia also recently made the following trade(s):</p>
<div class="lb-trans"><p>Sandip Kapadia 最近还进行了以下交易：</p>
</div><ul>
<li>On Thursday, January 15th, Sandip Kapadia sold 20,961 shares of Harmony Biosciences stock. The shares were sold at an average price of $35.92, for a total value of $752,919.12.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 1 月 15 日星期四，Sandip Kapadia 出售了 20,961 股 Harmony Biosciences 股票。股票以平均价格 $35.92 出售，总价值为 $752,919.12。</li>
</ul>
</div><p>Get <strong>Harmony Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Harmony Biosciences</strong> 警报：</p>
</div><h2>Harmony Biosciences Trading Down 2.2%</h2>
<div class="lb-trans"><h2>Harmony Biosciences 股价下跌 2.2%</h2>
</div><p>NASDAQ HRMY traded down $0.84 during trading on Wednesday, hitting $36.84. The stock had a trading volume of 503,087 shares, compared to its average volume of 597,958. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.12 billion, a PE ratio of 11.58, a PEG ratio of 0.35 and a beta of 0.84. The firm has a 50 day moving average price of $37.30 and a 200 day moving average price of $34.23. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87.</p>
<div class="lb-trans"><p>在周三的交易中，NASDAQ HRMY 股价下跌 $0.84，跌至 $36.84。该股票的交易量为 503,087 股，而其平均交易量为 597,958 股。该公司的速动比率为 3.72，流动比率为 3.75，债务与股本比率为 0.18。该公司的市值为 21.2 亿美元，市盈率为 11.58，市盈增长比率为 0.35，贝塔系数为 0.84。该公司 50 日移动平均价格为 $37.30，200 日移动平均价格为 $34.23。Harmony Biosciences Holdings, Inc. 的 12 个月低点为 $25.52，12 个月高点为 $40.87。</p>
</div><p>Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.05). Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. The business had revenue of $239.46 million during the quarter, compared to analysts' expectations of $222.68 million. As a group, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Harmony Biosciences (NASDAQ:HRMY - 获取免费报告) 最近一次发布季度财报是在 11 月 4 日星期二。该公司报告本季度每股收益为 $0.87，低于市场共识预期的 $0.92，差距为 ($0.05)。Harmony Biosciences 的净利润率为 22.50%，股本回报率为 24.88%。该公司在本季度的收入为 $239.46 百万美元，而分析师预期为 $222.68 百万美元。整体来看，股票研究分析师预测 Harmony Biosciences Holdings, Inc. 本年度每股收益将达到 2.43。</p>
</div><h2>Hedge Funds Weigh In On Harmony Biosciences</h2>
<div class="lb-trans"><h2>对 Harmony Biosciences 的对冲基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in HRMY. Amundi raised its holdings in Harmony Biosciences by 115.6% during the first quarter. Amundi now owns 39,668 shares of the company's stock worth $1,229,000 after purchasing an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Harmony Biosciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company's stock valued at $752,000 after buying an additional 984 shares during the last quarter. Empowered Funds LLC acquired a new stake in Harmony Biosciences during the 1st quarter worth $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Harmony Biosciences by 53.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company's stock worth $3,166,000 after acquiring an additional 33,058 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in Harmony Biosciences by 8.1% in the second quarter. State of Alaska Department of Revenue now owns 22,897 shares of the company's stock valued at $722,000 after acquiring an additional 1,724 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了在 HRMY 的持股。Amundi 在第一季度将其在 Harmony Biosciences 的持股提高了 115.6%。Amundi 现在拥有 39,668 股该公司的股票，价值 $1,229,000，此前在上个季度购买了额外的 21,266 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Harmony Biosciences 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 现在拥有 22,651 股该公司的股票，价值 $752,000，此前在上个季度购买了额外的 984 股。Empowered Funds LLC 在第一季度收购了 Harmony Biosciences 的新股份，价值 $2,330,000。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度将其在 Harmony Biosciences 的持股提高了 53.0%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 现在拥有 95,389 股该公司的股票，价值 $3,166,000，此前在上个季度收购了额外的 33,058 股。最后，阿拉斯加州财政部在第二季度将其在 Harmony Biosciences 的持股提高了 8.1%。阿拉斯加州财政部现在拥有 22,897 股该公司的股票，价值 $722,000，此前在上个季度收购了额外的 1,724 股。86.23% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research analysts recently issued reports on HRMY shares. Mizuho lifted their target price on Harmony Biosciences from $39.00 to $46.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, December 1st. HC Wainwright reiterated a &#34;buy&#34; rating on shares of Harmony Biosciences in a research note on Wednesday, December 3rd. Truist Financial lowered their price objective on Harmony Biosciences from $48.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research report on Thursday, January 8th. UBS Group reduced their target price on shares of Harmony Biosciences from $50.00 to $43.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded shares of Harmony Biosciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, December 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Buy&#34; and an average target price of $45.25.</p>
<div class="lb-trans"><p>一些研究分析师最近对 HRMY 股票发布了报告。瑞穗证券在 12 月 1 日星期一将 Harmony Biosciences 的目标价从 $39.00 提高至 $46.00，并在报告中给予该公司 &#34;跑赢大盘&#34; 的评级。HC Wainwright 在 12 月 3 日星期三的研究报告中重申了对 Harmony Biosciences 股票的 &#34;买入&#34; 评级。Truist Financial 在 1 月 8 日星期四的研究报告中将 Harmony Biosciences 的目标价从 $48.00 降至 $45.00，并为该公司设定了 &#34;买入&#34; 评级。瑞银集团在 10 月 15 日星期三的报告中将 Harmony Biosciences 股票的目标价从 $50.00 降至 $43.00，并对该股票设定了 &#34;买入&#34; 评级。最后，华尔街 Zen 在 12 月 13 日星期六的研究报告中将 Harmony Biosciences 股票的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。两位研究分析师对该股票给予了强烈买入评级，七位给予了买入评级，两位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;买入&#34;，平均目标价为 $45.25。</p>
</div><p><strong>View Our Latest Stock Report on Harmony Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Harmony Biosciences 股票报告</strong></p>
</div><h2>Harmony Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Harmony Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company's mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.</p>
<div class="lb-trans"><p>Harmony Biosciences Holdings, Inc 是一家商业阶段的生物制药公司，专注于开发和提供针对罕见神经和内分泌疾病患者的治疗方案。公司成立于 2017 年，总部位于宾夕法尼亚州普利茅斯会议，Harmony Biosciences 于 2020 年上市，并在纳斯达克以 HRMY 的股票代码交易。公司的使命是识别和推进能够满足现有治疗方案无法满足的患者群体的关键未满足需求的药物。</p>
</div><p>The company's flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.</p>
<div class="lb-trans"><p>该公司的旗舰产品是 WAKIX（pitolisant），这是美国批准的首个也是唯一的组胺 H3 受体拮抗剂/反向激动剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Harmony Biosciences</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
<li>Trump just signed it</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>Do not delete, read immediately</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Harmony Biosciences 更好</li>
<li>您的签名缺失 - 请在为时已晚之前采取行动</li>
<li>在星期一上午 9:30 购买此股票！</li>
<li>特朗普刚刚签署了它</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>请勿删除，立即阅读</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Harmony Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 $1,000 在 Harmony Biosciences 吗？</h2>
</div><p>Before you consider Harmony Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Harmony Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Harmony Biosciences 并不在名单上。</p>
</div><p>While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Harmony Biosciences 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sandip Kapadia 出售了 Harmony Biosciences（NASDAQ:HRMY）股票中的 3,746 股